IMU Biosciences has extended its Series A financing to more than $53 million (£40 million) in an oversubscribed round that will support expansion of its immune profiling platform and clinical programmes.

The round was co-led by IQ Capital and Molten Ventures, with participation from The British Business Bank and Meltwind alongside existing investors. The company said it has now raised a total of $60 million (£45 million).

London-based IMU is developing technology designed to provide a detailed picture of the immune system using a blood sample. The company combines multi-omic analysis with machine learning tools and said its platform can generate more than 100 million immune data points from a single sample.

According to IMU, its immune dataset has expanded to more than 25,000 individuals during 2026, supported by access to patient samples and clinical data. The company aims to establish what it describes as a universal standard for immune profiling that could help identify new disease mechanisms, monitor treatment responses and support more precise therapeutic decisions.

Funding from the latest round will be used to expand operations and continue development of the company’s clinical platform and infrastructure.

The capital will also support a number of ongoing clinical programmes, including work in stem cell transplantation, solid organ transplantation and immuno-oncology. Among these is the MANIFEST consortium, a UK research initiative investigating patient responses to cancer immunotherapies.

Dr John Baker, chief executive of IMU Biosciences, said: “We are delighted to announce IMU’s fundraise, which will allow us to expand our operations and develop our platform whilst continuing to deploy our groundbreaking technology across our clinical programmes as we work to fundamentally change how we understand, diagnose, and treat disease.”

Baker said the immune system remains poorly understood despite its central role in human health and disease.

He added that IMU’s combination of data resources and technology positions the company to support new discoveries and clinical decision-making. “With the largest immune system dataset globally and proprietary technology, IMU is uniquely positioned to fuel discoveries, devise treatments and empower clinicians; improving outcomes for patients across the full spectrum of human health and disease.”

Investors said the company’s ability to analyse the immune system at scale was a key factor behind their continued support.

Dr Inga Deakin, partner at Molten Ventures, said: “When we first invested in IMU in 2024, we believed deep immune profiling combined with AI could unlock something genuinely transformative in precision medicine. Our participation in this round reflects what we’ve seen since: a team that executes and a platform that delivers.”

Deakin added that the immune system sits at the centre of many diseases and that analysing it at high resolution could improve treatment selection for patients.

Dr Alex Wilson, partner at IQ Capital, said the company was helping to demonstrate the value of health data through its combination of large-scale immune datasets and machine learning analytics.

Meanwhile, Dr Carmine Circelli, senior investment director, life sciences at British Business Bank, said IMU’s approach provides an unprecedented view of the immune system and could help improve understanding and treatment of disease.

The financing comes as investors continue to show interest in companies applying artificial intelligence and large biological datasets to precision medicine, an area attracting increasing attention across the biotechnology sector.